Tioga Pharmaceuticals, Inc.

Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in Phase 2b Clinical Trials for Irritable Bowel Syndrome

05.20.2008
Tioga Pharmaceuticals, Inc. today announced that its oral kappa opioid receptor agonist, asimadoline, has demonstrated statistically significant results in treating Irritable Bowel Syndrome (IBS) patients in a recently completed 596 subject phase 2b randomized, double blind, placebo-controlled, dose ranging, clinical trial.

Asimadoline produced significant improvement in diarrhea-predominant patients across multiple parameters including: pain, urgency, frequency and bloating in both males and females. Effects occurred during the first month of treatment and persisted throughout the three months of treatment.

Benefit was also seen in alternating IBS patients. Asimadoline appeared to be well tolerated with no Adverse Event occurring in a dose-dependent manner. ...more

Tioga's lead product is asimadoline, a proprietary small molecule kappa opioid agonist, originally discovered by Merck KGaA of Darmstadt, Germany.
Asimadoline, is currently in clinical development for the treatment of irritable bowel syndrome (IBS) and functional dyspepsia (FD) ...more

IBS is a common condition that is found in high prevalence throughout the world. Affected patients experience recurrent episodes of abdominal pain or discomfort associated with a change in bowel pattern ...more

FUNCTIONAL DYSPEPSIA is defined as pain or discomfort in the upper abdomen for which no organic cause has been found ...more